Formulation and Evaluation of Thymoquinone-Loaded Transferosome Gel For the Treatment of Arthritis

Background: Arthritis is a debilitating chronic inflammatory condition with significant global burden. Thymoquinone (TQ), the principal bioactive constituent of Nigella sativa, possesses potent anti-inflammatory, antioxidant, and immunomodulatory properties. However, its BCS Class II classification, poor aqueous solubility (865.3 mg/L at 25°C) and log P of 2.20 restrict oral bioavailability. Transfersomes—ultra-deformable elastic phospholipid vesicles incorporating edge activators—offer a viable transdermal platform to overcome the stratum corneum barrier and achieve sustained local drug delivery at arthritic joints. Materials and Methods: TQ-loaded transfersomes were prepared by high-shear homogenisation (HSH) using soy lecithin, L-α-phosphatidylcholine (L-α-PC), and Tween 80. A three-factor, three-level Box–Behnken design (BBD; 15 runs; Design-Expert v12) was employed with soy lecithin concentration (A: 150–350 mg), L-α-PC (B: 100–300 mg), and RPM (C: 8000–10,000) as independent variables. Responses evaluated were zeta potential, particle size, encapsulation efficiency (EE%), and drug loading (DL%). FTIR compatibility studies and UV calibration (λmax 258 nm; R²=0.9987) were performed. Morphology was assessed by scanning electron microscopy (SEM; SRMIST Apreo S; 27 Feb 2024). In vitro drug release was conducted via Franz diffusion cells (cellophane membrane; pH 5.8; 37°C; 6 h). The optimised transferosome (F6) was incorporated into Carbopol 934 gel bases at three concentrations (TG1: 250 mg; TG2: 500 mg; TG3: 1000 mg) and evaluated for appearance, pH, spreadability, grittiness, and in vitro release. Results: FTIR spectra confirmed drug–excipient compatibility across all physical mixtures. SEM revealed spherical transfersomes with concentration-dependent clustering. Zeta potential ranged from −21.1 to −34.6 mV across 15 runs; optimal F6: −30.3 mV. Particle size ranged 316.6–715.6 nm; minimum achieved at soy lecithin 150–250 mg / L-α-PC 100–200 mg / 10,000 rpm. EE ranged from 54.53% (F5) to 77.1% (F1); DL ranged 16.97%–27.89% (maximum at soy lecithin 250 mg / L-α-PC 200 mg). Six-hour cumulative drug release (%CDR): F6=89.87%, F8=88.56%, F10=87.43%, F7=87.23%, F12=86.89%, F1=84.67%. Gel evaluation: TG2 exhibited optimal spreadability (1.99±0.08 g·cm/s), skincompatible pH (5.2), absence of grittiness, and highest CDR of 90.08% at 6 h. All gel formulations appeared clear and transparent. Conclusions: BBD-driven optimisation identified F6 as the optimal transferosome formulation. The F6-loaded TG2 gel demonstrated sustained transdermal drug release, ideal biopharmaceutical performance, and excellent topical applicability, establishing a promising platform for arthritis management. In vivo pharmacokinetic and antiinflammatory validation is warranted.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Delivery Technology
Published
2026-11-17
DOI
https://doi.org/10.25258/ijddt.16.80s.125
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Formulation and Evaluation of Thymoquinone-Loaded Transferosome Gel For the Treatment of Arthritis

V Hariharan, Sakthivel M, Deerga D, Sivakumar R et al.
3 links
International Journal of Drug Delivery Technology
Advancements in Transdermal Drug Delivery
article

Formulation and Evaluation of Thymoquinone-Loaded Transferosome Gel For the Treatment of Arthritis

V Hariharan, Sakthivel M, Deerga D, Sivakumar R, Myvizhi S, Thilagavathi S, ShaSiddiq A
article en

Abstract

Background: Arthritis is a debilitating chronic inflammatory condition with significant global burden. Thymoquinone (TQ), the principal bioactive constituent of Nigella sativa, possesses potent anti-inflammatory, antioxidant, and immunomodulatory properties. However, its BCS Class II classification, poor aqueous solubility (865.3 mg/L at 25°C) and log P of 2.20 restrict oral bioavailability. Transfersomes—ultra-deformable elastic phospholipid vesicles incorporating edge activators—offer a viable transdermal platform to overcome the stratum corneum barrier and achieve sustained local drug delivery at arthritic joints. Materials and Methods: TQ-loaded transfersomes were prepared by high-shear homogenisation (HSH) using soy lecithin, L-α-phosphatidylcholine (L-α-PC), and Tween 80. A three-factor, three-level Box–Behnken design (BBD; 15 runs; Design-Expert v12) was employed with soy lecithin concentration (A: 150–350 mg), L-α-PC (B: 100–300 mg), and RPM (C: 8000–10,000) as independent variables. Responses evaluated were zeta potential, particle size, encapsulation efficiency (EE%), and drug loading (DL%). FTIR compatibility studies and UV calibration (λmax 258 nm; R²=0.9987) were performed. Morphology was assessed by scanning electron microscopy (SEM; SRMIST Apreo S; 27 Feb 2024). In vitro drug release was conducted via Franz diffusion cells (cellophane membrane; pH 5.8; 37°C; 6 h). The optimised transferosome (F6) was incorporated into Carbopol 934 gel bases at three concentrations (TG1: 250 mg; TG2: 500 mg; TG3: 1000 mg) and evaluated for appearance, pH, spreadability, grittiness, and in vitro release. Results: FTIR spectra confirmed drug–excipient compatibility across all physical mixtures. SEM revealed spherical transfersomes with concentration-dependent clustering. Zeta potential ranged from −21.1 to −34.6 mV across 15 runs; optimal F6: −30.3 mV. Particle size ranged 316.6–715.6 nm; minimum achieved at soy lecithin 150–250 mg / L-α-PC 100–200 mg / 10,000 rpm. EE ranged from 54.53% (F5) to 77.1% (F1); DL ranged 16.97%–27.89% (maximum at soy lecithin 250 mg / L-α-PC 200 mg). Six-hour cumulative drug release (%CDR): F6=89.87%, F8=88.56%, F10=87.43%, F7=87.23%, F12=86.89%, F1=84.67%. Gel evaluation: TG2 exhibited optimal spreadability (1.99±0.08 g·cm/s), skincompatible pH (5.2), absence of grittiness, and highest CDR of 90.08% at 6 h. All gel formulations appeared clear and transparent. Conclusions: BBD-driven optimisation identified F6 as the optimal transferosome formulation. The F6-loaded TG2 gel demonstrated sustained transdermal drug release, ideal biopharmaceutical performance, and excellent topical applicability, establishing a promising platform for arthritis management. In vivo pharmacokinetic and antiinflammatory validation is warranted.

International Journal of Drug Delivery TechnologyVol. 16(80s)
American Association of Colleges of Pharmacy (US)
Good health and well-being
Advancements in Transdermal Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon